Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON (Nasdaq: IMNN) reported 2025 results and clinical progress on IMNN-001 for newly diagnosed advanced ovarian cancer. Final Phase 2 OVATION 2 data show continued median overall survival improvement: 14.7 months benefit (45.1 vs. 30.4 months) versus standard of care, and 24.2 months with PARP inhibitor maintenance (65.6 vs. 41.4 months).
Corporate actions include a December 2025 at-the-market registered direct offering (~$7.0M) and a strategic reorganization; 2025 net loss was $14.5M and year-end cash was $8.8M.
IMUNON (Nasdaq: IMNN) reported final Phase 2 OVATION 2 results showing an improved median overall survival (OS) benefit for IMNN-001 plus standard chemotherapy: a 14.7-month OS increase (45.1 vs. 30.4 months) versus SoC alone. Women receiving IMNN-001 plus PARP inhibitor maintenance showed a 24.2-month OS increase (65.6 vs. 41.4 months).
OVATION 2 randomized 112 patients. IMUNON says Phase 3 OVATION 3 enrollment is ahead of plan, currently open at seven sites with up to 43 sites considered and ~80 patients (~20% of 500 target) expected within a year; two interim OS analyses are planned.
IMUNON (Nasdaq: IMNN) will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its Phase 3 clinical program for IMNN-001.
To join, dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and reference Conference ID 4157104; a live webcast and a 90-day audio replay will be available. According to the company, the call will review 2025 results and clinical progress for IMNN-001.
IMUNON (Nasdaq: IMNN) announced a strategic reorganization to reduce nonessential headcount and redefine roles to lower operating expenses and prioritize its pivotal OVATION 3 Phase 3 ovarian cancer trial.
The company said Phase 3 enrollment remains ahead of schedule, and EVP/CSO Khursheed Anwer will retire effective February 20, 2026.
IMUNON (Nasdaq: IMNN) announced a registered direct offering to a single healthcare institutional investor for 1,939,114 shares of common stock (or pre-funded warrants) plus warrants to purchase up to 1,939,114 shares, at a combined purchase price of $3.61 per share and warrant (pre-funded warrant alternative at $3.6099).
The offering is expected to yield approximately $7.0 million gross, with warrants exercisable immediately at $3.482 and expiring five years from issuance; pre-funded warrants have a $0.0001 exercise price and do not expire. The offering will be made under the company’s Form S-3 shelf declared effective May 22, 2024, and is expected to close on or about December 31, 2025.
IMUNON (Nasdaq: IMNN) reported 2025 clinical and operational progress as it advances the pivotal Phase 3 OVATION 3 study of IMNN-001 in newly diagnosed advanced ovarian cancer and prepares toward a potential BLA filing. Key Phase 2 results cited include a 13-month median overall survival (OS) extension (HR 0.70) and an HR of 0.42 in a PARP inhibitor maintenance subgroup. Ongoing MRD translational data show IL-12 induction in macrophages, tumor microenvironment inflammation, lower MRD positivity and improved CRS/PFS signals. Company cites cost reductions in cGMP manufacturing and estimates $30 million to fund OVATION 3 HRD+ subgroup activities. Fast Track and Orphan Drug designations remain in place.
IMUNON (NASDAQ: IMNN) reported third quarter 2025 results and clinical progress on November 13, 2025. The company highlighted a median 13-month overall survival (OS) benefit observed with IMNN-001 in OVATION 2 and translational data showing tumor microenvironment shifts (CD8+ increases, reduced IDO/PD-L1/Treg) in 50-80% and 65-80% of paired samples. IMUNON described expanded Phase 3 OVATION 3 enrollment and an adaptive, event-driven trial design aligned with FDA precedents.
Financially, Q3 net loss was $3.4M (vs $4.8M prior year), operating expenses fell ~30%, and cash was $5.3M, which the company says funds operations into Q1 2026 while it pursues selective financing.
IMUNON (Nasdaq: IMNN) hosted a public webcast on Nov 10, 2025 presenting translational and clinical data for its DNA-mediated immunotherapy IMNN-001.
Speakers included cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 MRD trials, clinicians, statistical experts and IMUNON executives. The event highlighted clinical findings that the company described as showing significant potential for women with advanced ovarian cancer.
A recording and symposium slides are available on IMUNON’s Scientific Presentations page at https://investors.imunon.com/scientific-presentations.
IMUNON (Nasdaq: IMNN) held an R&D Day on Nov 10, 2025 in New York to present clinical updates for its DNA-mediated immunotherapy IMNN-001 in newly diagnosed advanced ovarian cancer.
Presentations reviewed Phase 2 OVATION 2 and an MRD study, highlighted a reported median 13-month overall survival (OS) benefit for IMNN-001 plus standard-of-care chemotherapy, safety and tolerability data, translational findings on tumor microenvironment remodeling, and progress on the pivotal Phase 3 OVATION 3 trial including activation and enrollment updates. A live webcast and materials were made available on the company scientific presentations page.
IMUNON (Nasdaq: IMNN) will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City with a live webcast option. The event features principal investigators discussing clinical progress for IMNN-001, a DNA-mediated IL-12 immunotherapy in Phase 3 development for advanced ovarian cancer, plus Phase 2 MRD results and Phase 3 statistical design.
Speakers include investigators from Washington University, MD Anderson, Berry Consultants, and IMUNON leadership covering OVATION 3/OVATION 2 data, MRD trial immune activation, trial design, enrollment momentum, and near-term clinical milestones. Registration is required to attend in person or virtually.